fda warning about semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease FDA warns against compounded GLP-1

Traditional Methods Both approaches offer distinct benefits depending on individual goals and preferences

"Long-Term Outcomes of Integrated Weight Management Programs." Published February 2026

In the SELECT trial, patients did not enroll for the specific purpose of weight loss and received standard of care covering management of CV risk factors, including medical treatment and healthy lifestyle counseling, but without a specific focus on weight loss

Semaglutide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Even more interesting, the decreased levels of glutathione and development of more diseases was a relationship found to be independent of age, sex, education, body mass index, and smoking status

Even occasional lapses have a measurable effect on efficacy over time